In adults taking PCSK9 inhibitors, higher fasting glucose levels before treatment are linked to a greater chance of developing type 2 diabetes, with each 1 mg/dL increase corresponding to a 10%...
Mechanism
Synthesis from 1 study
People with slightly high blood sugar already have insulin-producing cells working hard. A drug that increases cholesterol uptake into these cells pushes them over the edge—too much cholesterol damages them, and they can’t make enough insulin anymore. This turns prediabetes into full diabetes, and...
Most probable mechanism
When a person already has higher-than-normal blood sugar, their insulin-producing cells are under more stress. If they take a drug that increases the number of cholesterol-capturing receptors on these cells, the cells take in too much cholesterol, which damages them and makes it harder to release insulin. This pushes them from prediabetes into full diabetes.
Pancreatic beta-cells express low-density lipoprotein receptors (LDLR) on their surface, which internalize circulating low-density lipoprotein (LDL) particles.
Increased LDLR activity leads to elevated intracellular cholesterol accumulation within beta-cells.
Excess intracellular cholesterol disrupts cellular metabolism, induces endoplasmic reticulum stress, and impairs insulin synthesis and secretion.
In individuals with pre-existing glucose intolerance, beta-cells are already operating near functional capacity, making them more vulnerable to cholesterol-induced stress.
Progressive beta-cell dysfunction reduces insulin output, leading to failure to maintain normoglycemia and progression to overt type 2 diabetes.
Evidence from Studies
Supporting (1)
Community contributions welcome
Contradicting (0)
Community contributions welcome
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.